Machine signal
Active cluster sell — 3 distinct insiders, $559.2K, window ends Aug 3, 2026.
Figures computed from official regulatory filings — .
Analysttarget 17.25 USD (-7%) · consensus 3/5 · 0 buy · 5 hold · 0 sell
Ownershipinsiders 16.91% · institutions 80.25% · short 20.2% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Simulations Plus, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
4 buys346 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| DiBella John Anthony II | Sell | $18.3K | SEC |
| DiBella John Anthony II | Sell | $18.4K | SEC |
| WOLTOSZ WALTER S | Sell | $77K | SEC |
| Fiedler-Kelly Jill | Exercise | $73.9K | Unusual size | SEC |
| Fiedler-Kelly Jill | Sell | $133.8K | SEC |
| Fiedler-Kelly Jill | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Fiedler-Kelly Jill | Sell | $17.3K | SEC |
| Fiedler-Kelly Jill | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Fiedler-Kelly Jill | Exercise | $10.6K | SEC |
| DiBella John Anthony II | Sell | $16.5K | SEC |
| WOLTOSZ WALTER S | Sell | $261.5K | SEC |
| Fiedler-Kelly Jill | Sell | $16.5K | SEC |
| Fiedler-Kelly Jill | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Fiedler-Kelly Jill | Exercise | $10.1K | SEC |
| DiBella John Anthony II | Sell | $15K | SEC |
| WOLTOSZ WALTER S | Sell | $227K | SEC |
| WEINER DANIEL L | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Paglia John Kenneth | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Evans Sharlene | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| WOLTOSZ WALTER S | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| DiBella John Anthony II | Sell | $13.4K | SEC |
| DiBella John Anthony II | Exercise | $100K | SEC |
| DiBella John Anthony II | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Paglia John Kenneth | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Evans Sharlene | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |